Mesoblast sets Aug. 26 webcast on FY 2026 results
Mesoblast Limited (MESO) reports that it will host a webcast to discuss operational highlights and financial results for the full year ended June 30, 2026.
Rhea-AI Filing Summary
Mesoblast Limited (MESO) reports that it will host a webcast to discuss operational highlights and financial results for the full year ended June 30, 2026. The webcast is scheduled for 6:30 p.m. EDT on August 26, 2026 (8:30 a.m. AEST on August 27, 2026) and will be accessible via the company’s investor relations site.
Mesoblast describes itself as a global leader in developing allogeneic (off‑the‑shelf) cellular medicines for severe inflammatory conditions. Its product Ryoncil (remestemcel-L-rknd) is described as the first FDA‑approved mesenchymal stromal cell therapy, indicated for steroid‑refractory acute graft versus host disease in pediatric patients 2 months and older, with additional indications and pipeline programs under development.
Positive
- None.
Negative
- None.
Key Figures
Fiscal year end: June 30, 2026
Webcast time (EDT): 6:30 p.m. EDT, August 26, 2026
Webcast time (AEST): 8:30 a.m. AEST, August 27, 2026
+3 more
6 metrics
Fiscal year end
June 30, 2026
Full year period for operational highlights and financial results to be discussed on the webcast
Webcast time (EDT)
6:30 p.m. EDT, August 26, 2026
Scheduled start time of Mesoblast’s FY 2026 results webcast
Webcast time (AEST)
8:30 a.m. AEST, August 27, 2026
Corresponding Australian time for the FY 2026 webcast
Ryoncil pediatric indication age
2 months and older
Age range for pediatric patients with SR‑aGvHD eligible for Ryoncil therapy
Intellectual property portfolio size
over 1,000 granted patents or patent applications
Global IP covering compositions, manufacturing and indications
IP protection horizon
through to at least 2044
Stated commercial protection period in major markets
Key Terms
allogeneic cellular medicines, mesenchymal stromal cell, steroid-refractory acute graft versus host disease, biologic-resistant inflammatory bowel disease, +1 more
5 terms
allogeneic cellular medicines medical
"Mesoblast Limited (; N), global leader in allogeneic cellular medicines for inflammatory diseases"
Allogeneic cellular medicines are treatments made from living cells that are donated by one person and used to treat another. They function like biological patches or replacements, helping the body repair or fight disease. For investors, these medicines represent a promising area of healthcare innovation with the potential for widespread use, as they can be produced in large quantities and stored for off-the-shelf availability.
mesenchymal stromal cell medical
"first FDA-approved mesenchymal stromal cell (MSC) therapy"
Mesenchymal stromal cells are a type of adult cell found in bone marrow, fat and other tissues that can act like a repair crew, supporting tissue healing, reducing inflammation and helping other cells grow. Investors care because these cells are the basis for many experimental therapies and diagnostics; clinical success, manufacturing scale-up, safety and regulatory approval determine commercial potential and can strongly affect a company’s valuation.
steroid-refractory acute graft versus host disease medical
"Ryoncil ... for the treatment of steroid-refractory acute graft versus host disease"
An aggressive complication after an allogeneic stem cell or bone marrow transplant where donor immune cells attack the patient’s organs and tissues, and that does not improve after standard high‑dose steroid treatment. Investors should care because it signals a high unmet medical need, often requires additional therapies, longer hospital stays and complex clinical trials, and therefore drives demand, pricing and regulatory attention for new treatments.
biologic-resistant inflammatory bowel disease medical
"Ryoncil ... being developed for additional inflammatory diseases including ... biologic-resistant inflammatory bowel disease"
chronic low back pain medical
"Rexlemestrocel-L is being developed for heart failure and chronic low back pain"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Mesoblast (MESO) announce in this Form 6-K?
Mesoblast announced a webcast to discuss operational highlights and financial results for the full year ended June 30, 2026, along with a brief corporate and product pipeline overview.
When is Mesoblast’s MESO FY 2026 results webcast and how can it be accessed?
The webcast will be held at 6:30 p.m. EDT on August 26, 2026 (8:30 a.m. AEST on August 27, 2026) and can be accessed via https://webcast.openbriefing.com/msb-fyr-2026/ with an archived version available on Mesoblast’s investor webpage.
What is Ryoncil and what indication is it approved for?
Ryoncil (remestemcel-L-rknd) is described as the first FDA‑approved mesenchymal stromal cell therapy, indicated for steroid‑refractory acute graft versus host disease in pediatric patients 2 months and older.
What pipeline indications is Mesoblast (MESO) developing Ryoncil for?
Ryoncil is being developed for additional inflammatory indications, including steroid‑refractory acute graft versus host disease in adults and biologic‑resistant inflammatory bowel disease, according to the company’s description.
What other product candidate is Mesoblast developing and for which diseases?
Mesoblast is developing rexlemestrocel-L for heart failure and chronic low back pain, alongside its existing Ryoncil program for inflammatory diseases.
What does Mesoblast disclose about its intellectual property portfolio?
Mesoblast states it has a global intellectual property portfolio of over 1,000 granted patents or patent applications covering cell compositions, manufacturing methods and indications, providing commercial protection extending through at least 2044 in major markets.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934
For the month of August 2026
Commission File Number 001-37626
Mesoblast Limited
(Exact name of Registrant as specified in its charter)
Not Applicable
(Translation of Registrant’s name into English)
Australia
(Jurisdiction of incorporation or organization)
(Jurisdiction of incorporation or organization)
Silviu Itescu
Chief Executive Officer and Executive Director
Level 38
55 Collins Street
Melbourne 3000
Australia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:
Form 20-F ☑ Form 40-F ☐
INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K
On August 24, 2026, Mesoblast Limited filed with the Australian Securities Exchange a new release announcement, which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.
Mesoblast Limited | ||||||||||||||
| /s/ Paul Hughes | ||||||||||||||
| Paul Hughes | ||||||||||||||
| Company Secretary | ||||||||||||||
Dated: August 24, 2026
INDEX TO EXHIBITS
| Item | ||||||||
99.1 | Press release of Mesoblast Ltd, dated August 24, 2026. | |||||||
MESOBLAST FINANCIAL RESULTS AND CORPORATE UPDATE WEBCAST New York, USA, and Melbourne, Australia: August 24, 2026: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the full year ended June 30, 2026. The webcast will begin at 6.30pm EDT, Wednesday, August 26; 8.30am AEST, Thursday, August 27, 2026. It can be accessed via: https://webcast.openbriefing.com/msb-fyr-2026/ The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.com About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com. Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets. About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and X: @Mesoblast Release authorized by the Chief Executive. Exhibit 99.1
For more information, please contact: Corporate Communications / Investors Paul Hughes T: +61 3 9639 6036 Media – Global Media – Australia Rubenstein BlueDot Media Caroline Nelson Steve Dabkowski T: +1 703 489 3037 T: +61 419 880 486 E: cnelson@rubenstein.com E: steve@bluedot.net.au